ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

IXI Ixico Plc

8.10
-0.55 (-6.36%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ixico Plc LSE:IXI London Ordinary Share GB00BFXR4C20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.55 -6.36% 8.10 8.25 8.50 8.375 8.375 8.375 46,877 16:35:09
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

IXICO plc IXICO to Present at 10th Annual CNS Summit 2019

30/10/2019 9:00am

RNS Non-Regulatory


TIDMIXI

IXICO plc

30 October 2019

30 October 2019

IXICO plc

("IXICO" or the "Company")

IXICO to Present at 10(th) Annual CNS Summit 2019

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces that it is scheduled to attend and present at the 10th Annual CNS Summit held from 31(st) October to 3(rd) November 2019 in Boca Raton, Florida, USA.

10th Annual CNS Summit

31(st) October - 3(rd) November 2019, Boca Raton Resort, Florida, USA

Robin Wolz, Senior Vice President of Science & Innovation at IXICO will present a poster entitled "Automated sleep-wake prediction from wearable sensors using neural networks - from data collection to algorithm development, cross-validation and clinical trial deployment" during the evening receptions on Friday 1(st) and Saturday 2(nd) November 2019.

This study shows how AI technology improved the analysis of sleep/wake accelerometry from wearables compared to traditional, count-based measurements in a robust and reproducible way. Thus, the exploratory use of this validated algorithm in clinical trials is feasible and provides the collection of evidence needed to support further development of real-world evidence in clinical trial designs.

The rise in people using connected wearable devices has opened the door for the medical field to harness real-time patient health data to support clinical development of many diseases including Alzheimer's and Parkinson's disease.

Founded by R&D leaders, the CNS Summit is a platform of industry leaders working collaboratively to shape the future of the life sciences with a focus on innovation and technology. The agenda features top leaders from the regulators, pharmaceutical and biotech companies, technology and services companies driving change in the healthcare sector.

Poster authors:

Robin Wolz(1,2) , Luis Peraza(1) , Richard Joules(1) , Yves Dauvilliers(3)

Affiliations: 1- IXICO, London, UK, 2- Imperial College London, London, UK, 3- Department Neurology, Centre Hospitalier Universitaire, Montpellier, France

For further information please contact:

 
 IXICO plc                                     +44 (0) 20 3763 7498 
 Giulio Cerroni, Chief Executive Officer 
 Optimum Strategic Communications               +44 (0) 203 950 9144 
 Mary Clark / Supriya Mathur / Manel Mateus 
 IXICO@optimumcomms.com 
 

About IXICO

IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and rare disease.

Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience and rare disease, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

More information is available on www.IXICO.com

About CNS Summit

CNS Summit is a platform for change and a community passionate about shaping the future, with a focus on collaboration, innovation, and technology. Its mission is to have a positive impact on the success of clinical development programs. CNS Summit believes this mission is its ethical duty to the patients they serve by developing new treatments.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRABRBDGXXDBGCC

(END) Dow Jones Newswires

October 30, 2019 05:00 ET (09:00 GMT)

1 Year Ixico Chart

1 Year Ixico Chart

1 Month Ixico Chart

1 Month Ixico Chart

Your Recent History

Delayed Upgrade Clock